NCT03037645 - Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid Cancers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 28, 2017

Primary Completion Date

August 31, 2020

Study Completion Date

August 31, 2020

Conditions

Chronic Lymphocytic LeukemiaSmall Lymphocytic LymphomaLymphoplasmacytoid LymphomaMantle-Cell LymphomaWaldenstrom MacroglobulinemiaDiffuse Large B Cell LymphomaFollicular LymphomaMarginal Zone Lymphoma

Interventions

DRUG

SNS-062

SNS-062 will be orally administered twice daily and available in capsules containing either 25 mg or 100 mg of active ingredient.

Trial Locations (11)

10065

Weill Cornell Medicine, New York

21231

The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore

33612

Moffitt Cancer Center and Research Institute, Tampa

75702

Texas Oncology - Tyler, Tyler

77030

MD Anderson Cancer Center, Houston

92093

UC San Diego Moores Cancer Center, San Diego

97401

Willamette Valley Cancer Institute and Research Center, Eugene

98104

Swedish Cancer Institute, Seattle

98109

Fred Hutchinson Cancer Research Center, Seattle

92868-3201

University of California Irvine Medical Center, Orange

02215

Dana-Farber Cancer Institute, Boston